WHO ICTRP trial
A study to compare the preference of two contrasting paracetamol formulations in…
ACTRN12607000565448 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12607000565448 |
|---|---|
| Public title | A study to compare the preference of two contrasting paracetamol formulations in the management of osteoarthritis pain |
| Scientific title | A study to compare the preference of two contrasting paracetamol formulations in the management of osteoarthritis pain |
| Primary sponsor | GlaxoSmithKline Consumer Healthcare |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 4 |
| Countries | Australia |
| Conditions | Osteoarthritis of the knee; Osteoarthritis of the knee;Musculoskeletal - Osteoarthritis |
| Interventions | All patients will receive both treatments. Two weeks treatment with immediate release paracetamol (1000mg four times daily - oral), and two weeks of extended release paracetamol (1330mg three times daily - oral). There is no washout period… |
| Registration date | Jan 11, 2007 |
| Target size | 260 |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: